CA2886064A1 - Traitement de tumeurs du systeme nerveux central - Google Patents

Traitement de tumeurs du systeme nerveux central Download PDF

Info

Publication number
CA2886064A1
CA2886064A1 CA 2886064 CA2886064A CA2886064A1 CA 2886064 A1 CA2886064 A1 CA 2886064A1 CA 2886064 CA2886064 CA 2886064 CA 2886064 A CA2886064 A CA 2886064A CA 2886064 A1 CA2886064 A1 CA 2886064A1
Authority
CA
Canada
Prior art keywords
agents
ced
administered
cns
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2886064
Other languages
English (en)
Inventor
Krystof S. Bankiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of CA2886064A1 publication Critical patent/CA2886064A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2886064 2012-10-19 2013-10-18 Traitement de tumeurs du systeme nerveux central Abandoned CA2886064A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261716027P 2012-10-19 2012-10-19
US61/716,027 2012-10-19
PCT/US2013/065734 WO2014063087A1 (fr) 2012-10-19 2013-10-18 Traitement de tumeurs du système nerveux central

Publications (1)

Publication Number Publication Date
CA2886064A1 true CA2886064A1 (fr) 2014-04-24

Family

ID=50488796

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2886064 Abandoned CA2886064A1 (fr) 2012-10-19 2013-10-18 Traitement de tumeurs du systeme nerveux central

Country Status (8)

Country Link
US (1) US20150258085A1 (fr)
EP (1) EP2908909A1 (fr)
JP (1) JP2015534984A (fr)
CN (1) CN104736201A (fr)
AU (1) AU2013331077A1 (fr)
BR (1) BR112015008839A2 (fr)
CA (1) CA2886064A1 (fr)
WO (1) WO2014063087A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116763734A (zh) * 2017-03-31 2023-09-19 富士胶片株式会社 脂质体组合物的制造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
EP1448237A1 (fr) * 2001-11-09 2004-08-25 Neopharm, Inc. Traitement selectif des tumeurs exprimant l'interleukine 13
JP2009535360A (ja) * 2006-04-26 2009-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高分子量神経治療薬の対流増加送達のための組成物および方法
WO2008020931A2 (fr) * 2006-08-08 2008-02-21 Peak Biosciences, Inc. Dispositif pour l'administration d'agents anti-cancer à un tissu
EP2320903B1 (fr) * 2008-07-29 2017-01-18 Nerviano Medical Sciences S.r.l. COMBINAISON THÉRAPEUTIQUE CONTENANT UN INHIBITEUR DE CDKs ET UN AGENT ANTINÉOPLASTIQUE
AR076634A1 (es) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central

Also Published As

Publication number Publication date
CN104736201A (zh) 2015-06-24
JP2015534984A (ja) 2015-12-07
US20150258085A1 (en) 2015-09-17
AU2013331077A1 (en) 2015-04-16
WO2014063087A1 (fr) 2014-04-24
BR112015008839A2 (pt) 2017-07-04
EP2908909A1 (fr) 2015-08-26

Similar Documents

Publication Publication Date Title
EP3148529B1 (fr) Composés pour traiter le cancer du cerveau
JP7538268B2 (ja) αおよびγ－Ｄポリグルタミン酸化抗葉酸剤およびその使用
ES2275931T5 (es) Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
CA2743959C (fr) Composition liposomale pour administration amelioree par convection vers le systeme nerveux central
ES2826826T3 (es) Combinación farmacéutica que comprende irinotecán liposómico, oxaliplatino, 5-fluorouracilo y leucovorina para el tratamiento del cáncer pancreático metastático
US11344498B2 (en) Compositions and methods for on-demand high-efficiency triggerable anesthesia
US20150258085A1 (en) Treating Tumors of the Central Nervous System
US20220079935A1 (en) Compounds and treatments that enhance enteric nervous system function
TWI607766B (zh) 核酸、醫用奈米粒子組以及醫藥組合物
US20070148221A1 (en) Method of producing lipid complexed camptothecin-carboxylate
US20170368176A1 (en) Non-toxic topical anesthetic ophthalmic compositions
JP7576816B2 (ja) ポリグルタミン酸化抗葉酸剤およびその使用
US20210236424A1 (en) Binary lipid bilayer-containing vesicles comprising embedded cytotoxic agents and methods of making and using the same
WO2015148985A1 (fr) Encapsulation dans des liposomes de médicament
WO2005011698A1 (fr) Combinaison comportant un alcaloide de pervenche encapsules dans un liposome et un inhibiteur de topoisomerase ii, et utilisation de cette combinaison pour le traitement des neoplasies
JP2022517352A (ja) マイトマイシンｃのリポソーム化プロドラッグを含むリポソーム組成物および製造法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20171018